Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib + mFOLFOX6 in MEGAN
NCT02856867Phase 2Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2016
- Primary completion
- Jun 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of nintedanib in Esophago-Gastric Adenocarcinoma, sponsored by European Organisation for Research and Treatment of Cancer. Planned start Dec 2016; status: withdrawn.
02
Drugs
nintedanib
03
Conditions
Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on NCT02856867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02856867.